BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

595 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-09-30

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that among people with lower extremity peripheral artery disease (PAD), biomarker levels are higher during time periods immediately preceding an acute coronary event compared to time periods not immediately preceding an acute coronary event. Biomarkers the investigators will study are CRP, SAA, and D-dimer. Biomarkers will be measured at baseline and every two months during follow-up.

The primary aims of this study are as follows. Specific Aim #1. Among participants with PAD who experience an acute coronary event during follow-up, the investigators will determine whether biomarker levels measured immediately prior to the coronary event are higher than levels that do not immediately precede coronary events. Specific Aim #2, Part 1. The investigators will determine whether participants who experience a coronary event (cases) have higher biomarker levels at the visit immediately prior to the event than participants who have not experienced a coronary event (controls) at the time of the case event. Specific Aim #2, Part 2. The investigators will determine whether participants who experience a coronary event (cases) have a greater increase in biomarkers during the time period leading up to the event compared to participants who have not experienced a coronary event (controls).

To achieve these aims, the investigators will enroll up to 650 participants with PAD and follow them prospectively, measuring blood samples every two months, and ascertaining the presence of acute coronary events every two months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detecting Peripheral Artery Disease With the Pulse

NCT07226193

Peripheral Artery Disease (PAD)

NOT_YET_RECRUITING NA

Artificial Intelligence for Early Detection of Peripheral Artery Disease

NCT06505317

Peripheral Arterial Disease

NOT_YET_RECRUITING NA

The Frequency of Peripheral Arterial Disease in Patients with Deep Vein Thrombosis of the Lower Limbs

NCT06806540

Thromboembolism Peripheral Arterial Disease

RECRUITING

Biomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients

NCT04301362

Cancer Thromboembolism Thrombosis +1 more

UNKNOWN

Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease

NCT03161327

Peripheral Artery Disease Amputation Smoking +3 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PAD Participants

PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Peripheral arterial disease defined as an ABI less than or equal to 0.90 in either leg

We will also include PAD patients with an ABI \> 0.90 who meet any of the following criteria:

* History of documented lower extremity revascularization. A written report from the medical record will be required as documentation
* An angiogram demonstrating \>50% stenosis in one or more lower extremity arteries. Again, a written report will be required to document this. Participants with an angiogram noting moderate or greater stenosis will also be considered eligible, when a specific amount of stenosis is not denoted
* A report from the non-invasive vascular laboratory demonstrating a toe brachial pressure less than 0.60. Other criteria (i.e. PVR data) from the non-invasive vascular laboratory will not be considered sufficient for inclusion

Exclusion Criteria

* Treatment for cancer other than non-melanoma skin cancer during the previous 2 years. (However, persons treated for non-invasive breast cancer or prostate cancer during the previous year will be potentially eligible if their physician indicates that their life expectancy is \> 24 months, since non-invasive breast and prostate cancer often have an excellent prognosis)
* Unintentional weight loss of \> 7.5 pounds in the last six months;
* Mini-Mental Status Exam (MMSE) score \< 23 out of 30 or other history of cognitive impairment
* Communication difficulty due to language barriers
* Refusal to have regular blood draws or inability to obtain a blood sample at baseline
* Coronary or cerebrovascular event during the previous six months (these persons may become eligible at a later date)
* History of inflammatory arthritis (rheumatoid arthritis, lupus erythematosis, or polymyalgia rheumatic, gout), however participants with gouty arthritis will be eligible if the last episode was more than three months ago
* Residence more than 40 miles away from the medical center and unwillingness to travel to the medical center for every two month blood collection
* Unable to return for follow up testing for \> a consecutive six month period in the next two years
* Heart transplant surgery
* Major surgery (one that required general anesthesia) within the past 3 months These persons may become eligible at a later date

Eligible Sex

ALL

Accepts Healthy Volunteers

No